# 1. Financial Performance ## A. Key Figures * **Standalone Total Income:** **₹1,293 Cr** (Q2 FY26) (+3%) · **Consolidated Total Income:** +3% YoY * **Standalone PBT:** **₹111 Cr** (Q3 FY26) (+2%) · **Consolidated PBT (Continuing Ops):** **₹136 Cr** (+16%) * **Consolidated PAT (Incl. Discontinued):** **₹56 Cr** (Q3 FY26) vs. ₹96 Cr prior year * **Net Borrowings (Standalone):** **₹429 Cr** (up from ₹96 Cr as of Mar-25) ## B. Revenue Growth * **Modest Top-Line Expansion:** Standalone and consolidated revenues grew **3%**, reflecting stable demand but limited volume or pricing leverage. * **Other Income Composition:** No liability write-back this year; income driven by **foreign exchange gains** and **interest on intercompany loans**. ## C. Profitability Trends * **Divergent Profit Trajectories:** Continuing operations delivered **strong double-digit PBT growth**, led by improved performance at **ISGEC Hitachi Zosen Limited**, despite flat revenue. * **Margin Enhancement Strategy:** Project segment profitability has risen meaningfully over 4–5 years via disciplined bidding, now targeting **specialized engineering** and **export expansion** to push margins beyond current **5–7%** industry norms. * **Operational Profitability Confirmed:** Management affirms business generates **operational profit**, sufficient to partially service the **Isgec loan**, though **ROCE** remains undisclosed. ## D. Balance Sheet * **Borrowing Surge for Subsidiary Funding:** Standalone net borrowings more than quadrupled due to working capital needs, with **₹462 Cr ECB loan** routed through Singapore subsidiary to support **Cavite Biofuel** in the Philippines. * **Discontinued Ops Drag:** Losses from the Philippines plant, including **quarterly costs of ₹10–11 Cr**, are fully reflected in consolidated results. ## E. Cash Flow * **Receivables Unlock Ahead:** **₹400 Cr** in milestone-based retention payments from legacy FGD projects expected to be collected mostly within the year, with **₹40–50 Cr** spilling into next fiscal. --- # 2. Order Book & Demand ## A. Key Figures * **Standalone Orders Booked:** **₹1,208 Cr** (Sep-25Q) (+46%) · **Orders in Hand:** **₹7,754 Cr** (+26%) * **Consolidated Orders Booked:** **₹1,461 Cr** (Sep-25Q) (+64%) · **Orders in Hand:** **₹8,789 Cr** (+24%) * **Export Orders:** **₹1,644 Cr** (standalone) · **26%** of consolidated order book ## B. Orders Booked * **Robust Order Momentum:** Strong double-digit growth in both standalone and consolidated orders booked, signaling renewed demand traction across key industrial sectors. * **Healthy Demand Pipeline:** Encouraging inquiry levels, particularly in exports, with multiple international projects under negotiation supporting forward visibility. * **Sector Diversification:** Order book well-spread across **metals (steel), oil & gas, automobiles, cement, and core infrastructure**, reducing client and sector concentration risk. * **Execution Visibility:** Isgec Hitachi Zosen accounts for **₹937 Cr** of the order book, with typical delivery cycles of 12–18 months, extending for complex equipment. * **Revenue-Order Disconnect:** Despite a comfortable order book, recent revenue growth has been muted due to lack of large legacy orders, raising near-term execution timing concerns. ## C. Projects vs Manufacturing * **Divergent Execution Timelines:** Manufacturing segments like castings have short cycles (**1 month**), while EPC projects (e.g., boilers) span **20–28 months**, impacting revenue recognition pacing. ## D. Export Mix * **Export Recovery Underway:** Export contribution has rebounded to **26%** of the consolidated order book, reversing post-pandemic weakness and enhancing revenue diversification. --- # 3. Manufacturing & Capacity ## A. Key Figures * **New Facility Investment:** **₹87 Cr** for skids/modules at Dahej SEZ (Phase I: ₹65 Cr · Phase II: ₹22 Cr) * **Revenue from Expansions:** **₹225 Cr** annualized from Bhartoli facility · **₹275 Cr** upon full completion of Dahej expansion ## B. Capacity Expansion * **Strategic Site Development:** New manufacturing facility underway at **Bhartoli (25 km from Yamunanagar)**, set for commissioning by **July 2026**, to support Machine Building division and boost manufacturing revenue. * **Phased Export-Focused Investment:** Dahej SEZ expansion approved for **skids and modules** production, targeting export customers, with revenue contribution expected from next fiscal. * **Scalable Growth Roadmap:** Additional manufacturing expansions in pipeline, with investments under finalization, signaling long-term capacity scaling. ## C. Product Execution * **Feedstock Strategy:** Bioeq plant to utilize **molasses from Philippine sugar mills** during operational season, securing cost-effective and regionally optimized input supply. --- # 4. Product & Segment Performance ## A. Key Figures * **Legacy Order Book:** **₹300–400 Cr** (FGD-related) ## B. Boiler Demand * **Core Growth Driver:** Boilers remain the largest product line with strong demand and resilient pricing, underpinned by diversified feedstock operations in the Philippines. * **Operational Flexibility:** Philippines plant runs year-round, switching from sugarcane (mid-Dec to Apr) to molasses post-season, ensuring continuous utilization. ## C. Process Equipment * **Margin Pressure:** Competitive intensity has compressed process equipment margins, though management views the weakness as **temporary**. ## D. FGD Impact * **Declining Segment:** Air pollution control demand has weakened significantly due to government curbs on FGD mandates, marking a structural headwind. * **Wind-Down Timeline:** Remaining legacy FGD orders to be fully executed by **June 2026**, clearing a key overhang. --- # 5. Strategic & M&A Activity ## A. Key Figures * **Total Investment:** **₹1,076 Cr** in Bioeq Energy Holdings and subsidiaries (held for sale) * **Expected Profit:** **₹30–40 Cr** from transaction to offset interest on subsidiary loans ## B. Subsidiary Sale * **Sale Disrupted:** Transaction for Bioeq Energy Holdings and Philippine biofuel assets collapsed due to buyer default; assets remain classified as **held for sale** with results in discontinued operations. * **Ongoing Divestment Effort:** Active sale process continues with prospective buyers in due diligence; management committed to recovering **full ₹1,076 Cr investment**. * **Strategic Posture:** Company not under pressure to sell, willing to operate the asset to demonstrate performance and support valuation guarantees. ## C. Investment Recovery * **Recovery Mechanism:** Proceeds from eventual sale expected to yield **₹30–40 Cr profit**, primarily allocated to servicing long-term loan interest. ## D. Inorganic Growth * **Growth Pipeline:** Management is actively assessing inorganic opportunities to fill gaps in geography, client base, and business lines, though no deals are imminent. --- # 6. Risks & Operational Factors ## A. Key Figures * **Unrealized Orders:** **₹80–90 Cr** ready for dispatch, delayed by customer site readiness * **Bioeq Fixed Costs:** **₹10–11 Cr/quarter** average fixed costs contributing to subsidiary losses ## B. Customer Site Delays * **Near-Term Revenue Deferral:** Significant order value delayed due to unready customer sites, though no orders are on hold or at risk. * **Margin Improvement Strategy:** Project business poised for margin recovery through focus on **shorter-duration projects (≤30 months)** and avoidance of high-risk civil work. ## C. Forex & Funding * **Subsidiary Loss Drivers:** Bioeq’s quarterly loss attributed to **forex volatility** and interest costs, with structural fixed cost base in place. * **Limited U.S. Exposure:** No direct impact from U.S. tariffs due to negligible U.S. market presence; potential effects remain indirect and macro-linked. ## D. Sector Downturns * **Sugar Sector Weakness:** Continued muted outlook in sugar segment due to ongoing industry-wide downturn. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **7–8%** full-year outlook * **Post-Expansion Revenue:** **₹3,200–3,300 Cr** consolidated manufacturing run-rate (+₹700–800 Cr uplift) * **Bioeq Revenue:** **₹470–480 Cr** expected FY revenue * **Bioeq Profit:** **₹30–40 Cr** expected profit * **Capex Underway:** **₹230 Cr** currently in implementation ## B. Revenue Forecast * **Confident Growth Trajectory:** Full-year revenue and profit seen growing 7–8%, supported by a stronger order book and capacity expansion. * **Strategic Scale-Up:** Manufacturing revenue set to rise significantly post-expansion, with **₹400 Cr** of incremental revenue expected from current capex. * **Bioeq Milestone:** Business unit expected to become self-sustaining, covering all operational and interest costs while delivering a profit. ## C. Capex Plans * **Targeted Investment:** ₹230 Cr in active capex focused on scaling manufacturing capacity to meet multi-year demand visibility. * **Long-Term Confidence:** Leadership anticipates demand and margins will normalize over the next **4 to 5 years** due to broad-based industrial investments in India.